Work

373eP Circulating tumor DNA as a predictive biomarker for early-stage NSCLC

Year: 2026

Type: article

Abstract: Early detection remains the most significant factor in lung cancer survival. While Low-Dose CT (LDCT) has improved screening, false-positive rates remain high. Circulating tumor DNA (ctDNA) analysis, or liquid biopsy, provides a minimally invasive approach to detect molecular residual disease and characterize the genomic landscape of early-stage non-small cell lung cancer (NSCLC). This study evaluates the diagnostic synergy of ctDNA when integrated with standard imaging protocols.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2026.106686

Author: U. Huseynzada

Language: English

Topic: Cancer Genomics and Diagnostics

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910

OpenAlex ID: W7138019859

FWCI:

Cites:

Cited by:

Related to: